Press Releases

Biovica International AB – Annual report for the financial year 2020/2021 published

Annual report for the financial year 2020/2021 for Biovica International AB is published today on our website

June 30, 2021

Biovica Year-end Report February-April 2020/2021

Preparations for the launch of DiviTum®TKa

June 17, 2021

Biovica Capital Markets Day invitation June 9

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Wednesday 9 June from 14.00 to 16.30.

May 22, 2021

Biovica’s DiviTumTKa shows strong capabilities in malignant melanoma

May 20, 2021 – Biovica, active in cancer diagnostics, today announces that DiviTumTKa shows prognostic and predictive capabilities in metastatic cutaneous melanoma patients undergoing immunotherapy. These results from a new study at Karolinska University Hospital will be presented at the upcoming ASCO annual meeting, June 4-8, 2021.

May 20, 2021

Biovica strengthens the management team

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

April 29, 2021

DiviTum®TKa budget impact model results show potential for savings in cost of care

Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at the leading health economics and outcomes research conference, ISPOR 2021 in May.

April 23, 2021

Q3 Interim report November-January 2020/2021

FDA resumes review of DiviTum®TKa submission

March 18, 2021

Biovica’s DiviTumTKa prognostic for long-term outcome

Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment is prognostic for the long-term outcome of preoperative chemotherapy.

March 11, 2021

Nomination Committee for Biovica for the 2021 Annual General Meeting

The Nomination Committee prior to the 2021 Annual General Meeting will consist of three members, who shall represent the two shareholders with the most number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2020, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.

February 26, 2021

FDA resumes review of DiviTum®TKa submission

Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has resumed its review of Biovica’s 510(k)-submission for DiviTum®TKa.

January 29, 2021